Medroxyprogesterone: Nursing Drug Guide, Endometrial Protection & NCLEX Review

Medroxyprogesterone acetate is the generic progestin; nurses see it under several brand and combination names on MARs and pharmacy labels.

Common brands include Provera (oral tablets 2.5, 5, and 10 mg) and Depo-Provera CI (medroxyprogesterone acetate 150 mg/mL intramuscular suspension for contraception). MPA also appears in estrogen–progestin menopausal products (for example combined conjugated estrogen/MPA tablets) per individual product labeling.

Oral medroxyprogesterone acetate tablets are a progestin used for gynecologic hormone balance and endometrial protection during estrogen therapy. It may also appear in plans for conditions such as endometriosis per prescriber judgment. Intramuscular Depo-Provera CI is a separate contraceptive indication with its own boxed bone-density warning.

↔On a small screen, swipe or scroll sideways to see the full table.

Medroxyprogesterone acetate is a synthetic progestin that transforms proliferative endometrium into secretory endometrium when adequate estrogen is present. Orally at usual doses it does not reliably suppress ovulation; parenterally it inhibits gonadotropin production and prevents ovulation. In menopause care, nurses connect this to bedside checks: cyclic withdrawal bleeding may occur after a progestin course, and pairing with estrogen reduces unopposed estrogen endometrial stimulation per labeling clinical studies.

Dosing depends on indication and route. Oral tablet labeling gives specific regimens for amenorrhea, abnormal bleeding, and endometrial hyperplasia prevention; Depo-Provera CI uses 150 mg intramuscularly every 13 weeks for contraception. Use the lowest effective dose and reevaluate every 3–6 months.

Missed dose: Not specified in the reviewed prescribing information for oral tablets. If a dose is missed, do not double without prescriber or pharmacist guidance; for Depo-Provera CI, intervals greater than 13 weeks require pregnancy exclusion before the next injection per injectable labeling.

Pretreatment checks

• Confirm indication, route (oral vs IM), strength (2.5, 5, or 10 mg tablet), and cycle day for cyclic estrogen–progestin regimens; complete medication reconciliation for all hormone sources
• If patient takes systemic estradiol or other estrogen and has a uterus, verify medroxyprogesterone is on the MAR and was recently filled—unopposed estrogen increases endometrial cancer risk
• Pregnancy status when relevant (pregnancy test if indicated); active or history of deep vein thrombosis, stroke, MI, undiagnosed bleeding, or liver disease per contraindications

Contraindications

• Undiagnosed abnormal genital bleeding
• Known, suspected, or history of breast cancer; known or suspected estrogen- or progesterone-dependent neoplasia
• Active DVT, PE, arterial thromboembolic disease (stroke, MI), known liver impairment, known or suspected pregnancy, or anaphylaxis/angioedema to MPA

Important interactions

↔On a small screen, swipe or scroll sideways to see the full table.

Route: Oral tablet (2.5, 5, or 10 mg) swallowed with water; may take with or without food (food increases oral bioavailability). Depo-Provera CI 150 mg/mL given as deep IM injection in gluteal or deltoid muscle every 13 weeks—shake vial vigorously before use.

• Verify tablet strength and imprint (Provera 2.5, 5, or 10) before administration—strengths are not interchangeable
• For cyclic regimens with estrogen, confirm correct calendar days (e.g., days 1–14 or 15–28 of the cycle per prescriber order)
• For Depo injections: confirm pregnancy exclusion if interval exceeds 13 weeks; rotate IM sites; assess needle length for gluteal injection per Depo labeling

• Progestin withdrawal bleeding typically within 3–7 days after completing a 5–10 day oral course (when endometrium was estrogen-primed)
• Reduced endometrial hyperplasia risk when taken with daily conjugated estrogen in postmenopausal women with a uterus
• For Depo contraception: amenorrhea or irregular bleeding may occur; pregnancy prevention depends on on-time 13-week injections

Stop therapy and escalate per protocol when thrombotic, neurologic, or undiagnosed bleeding red flags appear—especially on combined estrogen–MPA therapy.

• Unilateral leg swelling, calf pain, or warmth—possible DVT; discontinue estrogen plus progestin if VTE occurs or is suspected
• Acute chest pain, pleuritic shortness of breath, or hemoptysis—possible pulmonary embolism; emergency escalation
• Sudden severe headache, vision change, weakness, or speech difficulty—possible stroke; discontinue therapy pending evaluation
• Persistent or heavy abnormal vaginal bleeding—requires diagnostic workup before continuing progestin or estrogen
• Anaphylaxis, angioedema, sudden vision loss, or jaundice—discontinue and emergency evaluation per labeling

Labeling separates adverse reactions reported with MPA tablets without concomitant estrogen from those reported with estrogen plus progestin therapy. Nurses prioritize thrombotic, bleeding, and breast-related signals.

↔On a small screen, swipe or scroll sideways to see the full table.

Overdosage of estrogen plus progestin therapy may cause nausea and vomiting, breast tenderness, dizziness, abdominal pain, drowsiness/fatigue, and withdrawal bleeding may occur in women per oral MPA labeling.

Management

• No specific antidote listed in the reviewed prescribing information—discontinue hormone therapy and provide supportive care
• Monitor vital signs, GI symptoms, and bleeding pattern
• Contact local poison control or medical toxicology services per facility protocol when ingestion is significant or symptoms are severe
• Document all estrogen and progestin sources—including patches, rings, and combination tablets

• Medroxyprogesterone vs methylprednisolone vs progesterone—read full generic name on MAR and label
• Provera vs Premarin—progestin vs estrogen; verify both when uterus is present
• MPA 2.5 mg vs 5 mg vs 10 mg—color-coded tablet strengths; independent double-check
• Oral Provera vs Depo-Provera IM—confirm route; never give oral dose intramuscularly
• Progestin omitted on MAR—critical error when estrogen continues and uterus is intact

↔On a small screen, swipe or scroll sideways to see the full table.

↔On a small screen, swipe or scroll sideways to see the full table.

Monitor

• Bleeding pattern—expected withdrawal bleed vs persistent abnormal bleeding
• VTE symptoms, blood pressure, weight, and edema especially on combined therapy
• Annual clinical breast exam and mammography; Pap smear per screening plan; endometrial sampling when indicated

Document

• Indication, dose, route, cycle days, and pairing with estrogen on MAR
• Patient teaching on thrombotic symptoms and missed progestin doses
• Hold events, pharmacy non-fill alerts, and 3–6 month reevaluation notes

• Take MPA exactly as prescribed with estrogen if you still have a uterus—do not skip the progestin pill even when vasomotor symptoms flare
• Report leg swelling, chest pain, sudden shortness of breath, severe headache, or vision changes immediately
• Report heavy or ongoing vaginal bleeding between cycles—do not assume all bleeding is normal
• Hormone therapy does not prevent heart disease; use the lowest dose for the shortest time that meets your treatment goal
• For Depo: return every 13 weeks; late injections require pregnancy check; long-term use may affect bone density per boxed warning

Do not give and contact the prescriber/pharmacist when:

Hold parameters may vary by institutional protocol. Follow prescriber orders, pharmacy guidance, and facility policy.

Practice NCLEX-style clinical judgment practice for medroxyprogesterone using a tabbed women’s-health case (MAR · Labs · History · Nursing notes) focused on progestin pairing and thrombotic risk, then work through priority action, SATA cue recognition, trend SATA, matrix urgency sorting, clinical judgment MCQ, and a documentation cloze—recognise cues → analyse → prioritise → act → evaluate outcomes.

Unfolding case. Diane is a 57-year-old postmenopausal woman with an intact uterus on conjugated estrogens 0.625 mg PO daily plus medroxyprogesterone acetate 10 mg PO daily for vasomotor symptoms. Pharmacy reports she has not filled MPA for 6 weeks. She reports daily spotting, left calf heaviness for 4 days, and one episode of pleuritic chest pain. Review the case tabs before the scheduled doses.

This medication guide is written and reviewed using NurseOnShift editorial and clinical review standards.

• Editorial Policy
• Medical Review Process
• Disclaimer

Educational use only. This content does not replace clinical judgment, prescriber orders, pharmacist guidance, product labeling, or institutional protocols.